Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various asp… Read more
Bio-Techne Corp (TECH) - Total Assets
Latest total assets as of December 2025: $2.52 Billion USD
Based on the latest financial reports, Bio-Techne Corp (TECH) holds total assets worth $2.52 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bio-Techne Corp - Total Assets Trend (1989–2025)
This chart illustrates how Bio-Techne Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bio-Techne Corp - Asset Composition Analysis
Current Asset Composition (June 2025)
Bio-Techne Corp's total assets of $2.52 Billion consist of 23.8% current assets and 76.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.3% |
| Accounts Receivable | $206.88 Million | 8.1% |
| Inventory | $189.45 Million | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $365.60 Million | 14.3% |
| Goodwill | $980.93 Million | 38.4% |
Asset Composition Trend (1989–2025)
This chart illustrates how Bio-Techne Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Techne Corp's current assets represent 23.8% of total assets in 2025, a decrease from 86.9% in 1989.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2025, down from 16.4% in 1989.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 1989.
- Asset Diversification: The largest asset category is goodwill at 38.4% of total assets.
Bio-Techne Corp Competitors by Total Assets
Key competitors of Bio-Techne Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Bio-Techne Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bio-Techne Corp generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Bio-Techne Corp generates $ 2.87 in net profit.
Bio-Techne Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.54 | 3.94 | 4.12 |
| Quick Ratio | 3.08 | 2.77 | 3.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $497.01 Million | $ 473.38 Million | $ 428.97 Million |
Bio-Techne Corp - Advanced Valuation Insights
This section examines the relationship between Bio-Techne Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.63 |
| Latest Market Cap to Assets Ratio | 3.07 |
| Asset Growth Rate (YoY) | -5.4% |
| Total Assets | $2.56 Billion |
| Market Capitalization | $7.85 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Bio-Techne Corp's assets at a significant premium ( 3.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Bio-Techne Corp's assets decreased by 5.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bio-Techne Corp (1989–2025)
The table below shows the annual total assets of Bio-Techne Corp from 1989 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $2.56 Billion | -5.40% |
| 2024-06-30 | $2.70 Billion | +2.47% |
| 2023-06-30 | $2.64 Billion | +14.99% |
| 2022-06-30 | $2.29 Billion | +1.41% |
| 2021-06-30 | $2.26 Billion | +11.61% |
| 2020-06-30 | $2.03 Billion | +7.60% |
| 2019-06-30 | $1.88 Billion | +18.28% |
| 2018-06-30 | $1.59 Billion | +2.35% |
| 2017-06-30 | $1.56 Billion | +37.82% |
| 2016-06-30 | $1.13 Billion | +6.22% |
| 2015-06-30 | $1.06 Billion | +23.29% |
| 2014-06-30 | $862.49 Million | +10.85% |
| 2013-06-30 | $778.10 Million | +8.17% |
| 2012-06-30 | $719.32 Million | +16.46% |
| 2011-06-30 | $617.67 Million | +19.05% |
| 2010-06-30 | $518.82 Million | +9.92% |
| 2009-06-30 | $472.00 Million | -6.97% |
| 2008-06-30 | $507.37 Million | +11.55% |
| 2007-06-30 | $454.84 Million | +22.76% |
| 2006-06-30 | $370.51 Million | +25.49% |
| 2005-06-30 | $295.26 Million | -9.28% |
| 2004-06-30 | $325.46 Million | +23.62% |
| 2003-06-30 | $263.28 Million | +10.51% |
| 2002-06-30 | $238.25 Million | +10.54% |
| 2001-06-30 | $215.53 Million | +19.46% |
| 2000-06-30 | $180.41 Million | +45.73% |
| 1999-06-30 | $123.80 Million | +69.82% |
| 1998-06-30 | $72.90 Million | +35.25% |
| 1997-06-30 | $53.90 Million | +21.40% |
| 1996-06-30 | $44.40 Million | +30.21% |
| 1995-06-30 | $34.10 Million | +27.24% |
| 1994-06-30 | $26.80 Million | +31.37% |
| 1993-06-30 | $20.40 Million | +29.94% |
| 1992-06-30 | $15.70 Million | +63.54% |
| 1991-06-30 | $9.60 Million | +20.00% |
| 1990-06-30 | $8.00 Million | +31.15% |
| 1989-06-30 | $6.10 Million | -- |